Product Monograph ZANTAC - GlaxoSmithKline

In addition, ZANTAC ® is indicated for the prophylaxis and maintenance treatment ofduodenal or benign gastric ulcer in patients with a history of recurrent ulceration.CONTRAINDICATIONSZANTAC ® (ranitidine hydrochloride) is contraindicated for patients known to havehypersensitivity to ranitidine or to any ingredient in the formulation. For a completelisting, see COMPOSITION.WARNINGSGastric UlcerTreatment with a histamine H 2 -antagonist may mask symptoms associated withcarcinoma of the stomach and, therefore, may delay diagnosis of that condition.Accordingly, where gastric ulcer is suspected the possibility of malignancy should beexcluded before therapy with ZANTAC ® (ranitidine hydrochloride) is instituted.Concomitant NSAID UseRegular supervision of patients who are taking non-steroidal anti-inflammatory drugsconcomitantly with ZANTAC ® is recommended especially in the elderly and in those witha history of peptic ulcer. Baseline endoscopy and histological evaluation is necessary torule out gastric carcinoma.Use in Patients with a History of Acute PorphyriaRare clinical reports suggest that ranitidine may precipitate acute porphyric attacks.Therefore, ranitidine should be avoided in patients with a history of acute porphyria.FertilityThere are no data on the effects of ZANTAC ® on human fertility. There were no effectson male and female fertility in animal studies (see TOXICOLOGY).February 18, 2014Page 6 of 41